A Study of the Equivalent Effectiveness of 400 mcg Mometasone Furoate Using Two Different Dry Powder Inhalers in Moderate Asthmatics (Study P04828)

NCT00521599 | Completed Phase 4 Results

• 1 other identifier: P04828
• Study Type: interventional
• Target: 672
• Locations: 0 countries
• Sites: N/A

Brief Summary

This study is a placebo-controlled study with 8-weeks of double-blind treatment of mometasone furoate dry powder inhaler (MF DPI) 200 mcg twice daily (BID) using two different inhalers, preceded by the Screening Period and by 2 weeks of open-label treatment with one inhalation of MF DPI 200 mcg twice daily in corticosteroid-dependent asthmatic subjects. The objective of this study is to evaluate the therapeutic equivalency of the 100 mcg and 200 mcg MF DPIs when providing the same total daily dose (400 mcg/day).

Conditions

Asthma

Outcome Measures

Primary Outcomes (1)

• Change From Baseline in the Average AM Peak Expiratory Flow (PEF) Over the 7 Days of Week 8.

  Week 8 End = The last 7 days of data with the last day within the range of Days 51 to 64.

  Baseline and Week 8 End

Study Arms (3)

MF DPI 2 x 100 mcg BID

EXPERIMENTAL

2 inhalations of mometasone furoate dry powder inhaler (MF DPI) 100 mcg plus 1 inhalation of placebo matching MF DPI 200 mcg twice daily (BID) for 8 weeks

Drug: Mometasone furoate dry powder inhaler; Drug: Placebo

MF DPI 1 x 200 mcg BID

EXPERIMENTAL

1 inhalation of mometasone furoate dry powder inhaler (MF DPI) 200 mcg plus 2 inhalations of placebo matching MF DPI 100 mcg twice daily (BID) for 8 weeks

Drug: Mometasone furoate dry powder inhaler; Drug: Placebo

Placebo

PLACEBO COMPARATOR

2 inhalations of placebo matching mometasone furoate dry powder inhaler (MF DPI) 100 mcg plus 1 inhalation of placebo matching MF DPI 200 mcg twice daily (BID) for 8 weeks

Drug: Placebo

Interventions

Mometasone furoate dry powder inhaler DRUG

Also known as: Asmanex

MF DPI 1 x 200 mcg BID; MF DPI 2 x 100 mcg BID

Placebo DRUG

MF DPI 1 x 200 mcg BID; MF DPI 2 x 100 mcg BID; Placebo

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• years of age, either sex, any race, with a diagnosis of asthma of at least 12 months' duration.
• Must be on a stable regimen of a medium daily dose of ICS for at least 4 weeks immediately prior to Screening. Medium daily doses of ICS are:
• \>500 to 1000 mcg beclomethasone CFC
• \>250 to 500 mcg beclomethasone HFA
• \>600 to 1000 mcg budesonide DPI
• \>1000 to 2000 mcg flunisolide
• \>250 to 500 mcg fluticasone
• mcg MF
• \>1000 to 2000 mcg triamcinolone acetonide.
• Must have a documented reversibility test obtained within 12 months prior to signing the informed consent form. Otherwise, to document a diagnosis of asthma and ensure the subject's responsiveness to bronchodilators, one of the following methods can be used at the Screening Visit, or thereafter, but prior to the Baseline Visit:
• An increase in absolute FEV1 of \>=12% and \>=200 mL within 30 minutes of administration of 4 puffs of albuterol.
• A PEF variability of \>20%, expressed as a percent of the best and lowest morning pre-bronchodilator PEF over at least 1 week.
• A diurnal variation in PEF of \>20% based on the difference between the pre-bronchodilator AM value and the post-bronchodilator value from the evening before, expressed as a percentage of the mean daily PEF value any day during the Run-in Period.
• At Screening and Baseline, the subject's FEV1 must be \>=60% predicted, when all restricted medications have been withheld for the appropriate intervals. If, based on the clinical judgment of the investigator, there is no harm in changing the subject's asthma therapy, subjects on LABAs must be willing to discontinue the LABA and be transferred to open-label treatment with MF MDI 200 mcg BID for 2 weeks prior to randomization.
• Clinical laboratory tests conducted at the Screening Visit must be within normal limits or clinically acceptable to the investigator/sponsor before the subject is instructed to start using open-label MF DPI run-in medication. A chest x-ray performed at the Screening Visit or any type of chest imaging within 12 months prior to the Screening Visit must be clinically acceptable to the investigator.

You may not qualify if:

• A change in absolute FEV1 of \>20% at any time from the Screening Visit up to and including the Baseline Visit.
• A clinical asthma exacerbation (defined as a deterioration of asthma that results in emergency treatment, hospitalization, or treatment with additional, excluded asthma medication at any time from the Screening Visit up to and including the Baseline Visit).
• Treatment in the emergency department or admission to the hospital for an asthma exacerbation 12 months prior to Screening.
• An upper or lower respiratory tract infection within the 4 weeks of to Screening. Visits can be rescheduled to meet this requirement.
• Evidence of clinically significant oropharyngeal candidiasis at Baseline with or without treatment. If there is evidence of oropharyngeal candidiasis at Screening and/or during the MF DPI Run-in Period, the subject may be treated as appropriate and the Baseline Visit can be scheduled upon resolution. If there is evidence of oropharyngeal candidiasis at the Baseline Visit, the subject may be treated as appropriate and the visit can be rescheduled upon resolution.
• A smoker or ex-smoker and has smoked within the previous year or has had a cumulative smoking history \>10 pack-years.
• Requires more than twelve inhalations of albuterol or more than 2 treatments with nebulized beta-agonists on any 2 consecutive days during the Run-in Period.
• Ever required mechanical ventilation secondary to an asthma exacerbation.

Sponsors & Collaborators

• Organon and Co: lead

MeSH Terms

Conditions

Asthma

Interventions

Mometasone Furoate

Condition Hierarchy (Ancestors)

Bronchial Diseases; Respiratory Tract Diseases; Lung Diseases, Obstructive; Lung Diseases; Respiratory Hypersensitivity; Hypersensitivity, Immediate; Hypersensitivity; Immune System Diseases

Intervention Hierarchy (Ancestors)

Pregnadienediols; Pregnadienes; Pregnanes; Steroids; Fused-Ring Compounds; Polycyclic Compounds

Results Point of Contact

• Title: Senior Vice President, Global Clinical Development
• Organization: Merck Sharp & Dohme Corp.

ClinicalTrialsDisclosure@merck.com

Publication Agreements

• PI is Sponsor Employee: No
• Restriction Type: OTHER
• Restrictive Agreement: Yes

Study Design

• Study Type: interventional
• Phase: phase 4
• Allocation: RANDOMIZED
• Masking: DOUBLE
• Who Masked: PARTICIPANT, INVESTIGATOR
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: August 27, 2007
• First Posted: August 28, 2007
• Study Start: May 1, 2007
• Primary Completion: March 1, 2009
• Study Completion: March 1, 2009
• Last Updated: May 23, 2024
• Results First Posted: March 23, 2010

Record last verified: 2022-02

Data Sharing

• IPD Sharing: Will not share